DarioHealth announced a new contract with a leading nationwide Pharmacy Benefits Manager operating in 50 states to provide Dario’s digital therapeutics, starting with the diabetes solution, to employer clients beginning in the second quarter of 2023. Through the new contract, the PBM will replace an existing digital diabetes solution with Dario’s proven cardio metabolic digital therapeutic. Dario’s solution joins a growing roster of digital health solutions for the PBM, one of the top ten digitally-enabled PBM platforms in the country. Members who are currently users of the PBM’s digital diabetes offering will be transitioned to Dario upon launch, which is expected to generate revenue in the second quarter and grow significantly through the rest of 2023. Post-launch, Dario’s solutions will be part of the PBM offering to their recent and future customer additions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DRIO:
- Amwell expands digital clinical programs through partnership with DarioHealth
- DarioHealth announces partnership with Amwell
- DarioHealth reports Q4 revenue $6.8M, consensus $6.29M
- DarioHealth Reports Fourth Quarter and Record Revenue in Full-Year 2022 Financial and Operating Results
- DarioHealth announces new clinical studies to be presented at ATTD 2023